Comparisons of Treatment Responses of Early Syphilis to 2.4 Milliunits (MU) Single-dose Benzathine Penicillin G With or Without Doxycycline in People Living With HIV

This randomized controlled superiority study will be conducted during 2023-2025. The eligible participants are adult people living with HIV (PLWH) who are newly diagnosed with early syphilis. Participants will be randomized in a 1:1 ratio to receive single-dose benzathine penicillin G (BPG) (2.4 MU intramuscularly once) plus doxycycline (100 mg orally twice daily for 7 days) or single-dose BPG. The primary outcome is serologic response, defined as a decline of rapid plasma reagin (RPR) titer by 4-fold or greater, at week 24 and week 48; and the secondary outcomes include microbiologic response of syphilis and bacterial sexually transmitted infections (STIs) assessed by nucleic-acid amplification test (NAAT) at week 4.

开始日期2024-01-01

申办/合作机构

National Taiwan University Hospital

[+6]

ACTRN12624000333516 / Recruiting临床2期

Safety, tolerability and acceptability of high dose, subcutaneous injection of benzathine penicillin G (Bicillin® L-A) in children and young adults with rheumatic fever

开始日期2023-06-01

申办/合作机构

University of Otago

NCT05980871 / Active, not recruiting临床4期IIT

Treatment Responses of Early Syphilis to Single-dose Ceftriaxone Plus Doxycycline Versus Single-dose Benzathine Penicillin G Plus Doxycycline in PLWH

In a prospective study investigating the prevalence of STIs among at-risk PLWH, the prevalence of Chlamydia trachomatis and N. gonorrhoeae was 24.7% and 12.1%, respectively. Surprisingly, the study found high rates of C. trachomatis and/or N. gonorrhoeae co-infections in PLWH with recent hepatitis C virus (HCV) infection (50%), HBsAg positivity (44%), and early syphilis (36%). Considering the high rate of sexually transmitted co-infections, combination therapy of single-dose ceftriaxone plus 7-day doxycycline for early syphilis may provide convenience and benefit to treatment of N. gonorrhoeae and C. trachomatis co-infections at a single clinic encounter. In the present study, this study aim to compare the efficacy of ceftriaxone plus doxycycline versus BPG plus doxycycline as the treatment for early syphilis among PLWH.

开始日期2023-03-10

申办/合作机构

National Taiwan University Hospital

100 项与苄星青霉素相关的临床结果

登录后查看更多信息

100 项与苄星青霉素相关的转化医学

登录后查看更多信息

100 项与苄星青霉素相关的专利（医药）

登录后查看更多信息

553

项与苄星青霉素相关的文献（医药）

2025-01-01·Theriogenology

Serial frequent or multiple Tru-cut® testicular biopsies in rams enable assessment of histological characteristics or transcriptional profiles, with no acute or chronic adverse effects

Article

作者: Nunes, S G ; Uzae, K.Z. ; Castilho, A C S ; Carvalho, J C ; Nunes, S.G. ; Kastelic, J.P. ; Ferreira, J.C.P. ; Rattes, P Z ; Uzae, K Z ; Rizzoto, G ; Kastelic, J P ; Nogueira, G P ; Di Santis, G W ; Denadai, R ; Denadai, R. ; Mogollón García, H.D. ; Ribeiro, G C ; Carvalho, J.C. ; Navolar, F M N ; Di Santis, G.W. ; Pupulim, A.G.R. ; Ribeiro, G.C. ; Mogollón García, H D ; Castilho, A.C.S. ; Rattes, P.Z. ; Nogueira, G.P. ; Pupulim, A G R ; Navolar, F.M.N. ; Rizzoto, G. ; Ferreira, J C P

This study aimed to evaluate the feasibility of performing multiple testicular biopsies in rams using Tru-cut® needles, assessing histological structure, gene expression, and potential complications such as effects on semen quality, testicular blood flow, and ultrasonographic echotexture. In Exp. 1, six mature rams underwent testicular biopsies at intervals (0, 3, 6, 12, 24, and 48 h) using a 16 G Tru-cut® needle, with alternating testes for each collection. Benzathine benzylpenicillin and flunixin meglumine were administered for infection and inflammation control. Local anesthesia and post-biopsy care included lidocaine, digital pressure, and ice application. Testicular samples were analyzed for gene expression related to inflammation, oxidative stress, and steroidogenesis. Semen quality was assessed pre-biopsy and 28 days post-biopsy. Ultrasonographic evaluations of the scrotum and testes were conducted before biopsies and on days 5, 9, 13, 17, and 21 post-biopsies. In Exp. 2, a second group of six mature rams underwent biopsies using 14 G needles, with two samples taken from each testis. Samples were histologically examined for structural preservation. Scrotal skin temperature was measured using infrared thermography, and testicular blood flow was assessed via color Doppler ultrasonography, with measurements taken before and on days 1, 2, 4, 6, 8, 10, 25, 50, 75, and 100 post-biopsies. Semen collection followed the same schedule as in Exp. 1. In Exp. 3, biopsies were performed on different testicular regions (upper, middle, lower) using 12 G, 14 G, and 16 G needles to compare structural preservation. Samples were histologically analyzed. No clinical signs of injury, inflammation, or fluid accumulation were observed. Scrotal pain, increased temperature, swelling, and bleeding were absent, and behavioral signs indicative of pain were not detected. Gene expression remained unchanged, and no significant alterations in seminal characteristics or testicular echogenicity were observed. A slight increase in resistivity and pulsatility indices was noted in Exp. 2. Biopsies with 14 G and 16 G needles resulted in structural disruptions, while 12 G needles better preserved testicular parenchyma. Multiple testicular biopsies using Tru-cut® needles did not cause significant morphological changes, alter transcriptional profiles, or affect semen or ultrasonographic characteristics, demonstrating that this method is viable for monitoring acute molecular changes in the testes.

2024-11-01·International Journal of Dermatology

Ulcerative erythematous papules and plaques on the face and lower legs of a man living with HIV: a clinicopathological challenge

Article

作者: Leslie, Kieron S. ; Coates, Sarah J. ; McKenzie, Ning C. ; De la Sancha, Carlo ; Hickey, Matthew D.

AbstractA 44‐year‐old male presented with a 2‐month history of erythematous ulcerative papules and plaques on the scalp, face, and bilateral lower legs. He had a 5‐year history of well‐controlled HIV on antiretroviral therapy and recurrent syphilis infections. His face had violaceous plaques, while bilateral ankles and calves had ulcerative lesions with necrotic centers and purple borders. The morphologies clinically mimicked pyoderma gangrenosum on the lower extremities and cutaneous lymphoma on the face. Biopsy and reactive rapid plasma reagin confirmed a diagnosis of lues maligna, and the patient was successfully treated with penicillin G benzathine.

2024-10-01·eClinicalMedicine

Local anaesthetic to reduce injection pain in patients who are prescribed intramuscular benzathine penicillin G: a systematic review and meta-analysis

Article

作者: Pelone, Ferruccio ; Ahmad, Mahmood ; Celermajer, David S. ; Bray, Jonathan Jh ; Cassandra, Miryan ; Shokraneh, Farhad ; Providencia, Rui ; Ahmed, Sabahat ; Kilic, Yakup ; Kwok, Bessie ; Bray, Jonathan JH. ; Marijon, Eloi ; Ali, Syed Ahsan ; Ahmed, Nida ; Celermajer, David S

BackgroundThree to 4-weekly intramuscular injections of benzathine penicillin G (BPG) for a prolonged period (e.g., 10 years, until age 40 years, or lifelong) are recommended for preventing group A streptococcal infections that cause recurrent acute rheumatic fever (ARF) and potential progression to rheumatic heart disease (RHD). The duration of treatment, frequency and local pain associated with BPG injections may lead to reduced compliance. Shorter courses of BPG are recommended for the treatment of syphilis and Streptococcal infections. We aimed to assess the effects of local anaesthesia in reducing injection pain in patients who are being treated with BPG.MethodsIn this systematic review and meta-analysis, we searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Conference Proceedings Citation Index-Science and LILACS from database inception up to May 4, 2024, and performed additional searches for grey literature. Randomised controlled trials comparing BPG vs. BPG administered alongside local anaesthetics were included. Randomized controlled trials using BPG, irrespectively of indication, and testing any local anaesthetic agent for pain alleviation were considered eligible. We applied GRADE to assess the quality of evidence. Summary data were extracted from included trials. The primary outcome was injection pain, assessed through mean differences. A random-effects model was utilized to account for study heterogeneity. This study is registered with PROSPERO, CRD42022342437.FindingsDatabase searches identified a total of 3958 records, and 3 additional records were retrieved from grey literature searches. After removal of duplicates, screening of abstracts and full-text review, eight trials were included, combining a total of 489 patients (151 patients with RHD). Immediate pain level, as reported by patients, was of high intensity in most studies. Low intensity pain was still reported at 24 h. Administration of lidocaine mixed with BPG was associated with a significant reduction in immediate post-injection pain (mean difference -3.84, 95% confidence interval -6.19 to -1.48, P = 0.0001; 4 studies; I² = 98%; GRADE: moderate quality), pain at 5 min (mean difference -2.85, 95% CI confidence interval -3.78 to -1.92, P < 0.0001; 1 study; GRADE: moderate quality), and pain at 20 min (mean difference -1.85, 95% confidence interval -2.61 to -1.09, P < 0.0001; 1 study; GRADE: moderate quality) on a 1 to 10 scale. One study assessed lidocaine cream applied to the skin prior to BPG injection and showed no significant reduction in injection pain (mean difference = -0.54, 95% CI confidence interval -1.17 to 0.09, P = 0.13; 1 study; GRADE: low quality). Mepivacaine mixed with BPG in patients with syphilis showed a significant reduction of immediate post-injection pain (mean difference -2.19, 95% CI confidence interval -2.49 to -1.89, P < 0.0001; 1 study; GRADE: moderate quality). Two studies assessed procaine mixed with BPG and reported: lower immediate pain levels or pain assessed at 1 h (mean difference and 95% CI confidence intervals not provided, P = 0.001 and P = 0.008, respectively; 1 study; GRADE: low quality), or less immediate pain and pain at 24 h on the buttock injected with procaine mixed with BPG (mean difference and 95% CI confidence intervals not provided, P < 0.001 for both; 1 study; Grade: low quality). No severe adverse reactions were reported.InterpretationIn patients receiving intramuscular BPG injections, moderate quality quantitative evidence suggests that BPG injections diluted with lidocaine or mepivacaine may improve post-injection pain scores compared to BPG injections diluted with sterile water. Procaine may also have a benefit, but quality of evidence was lower. Most studies included small patient samples and assessed pain levels at different timepoints. Due to insufficient data we were not able to assess the impact of injection volume, and local anaesthetics' dose on pain intensity and duration of pain relief.FundingWHO.

项与苄星青霉素相关的新闻（医药）

2024-11-12

·drugs

Genomic Test Might Quickly Diagnose Any Type of Infection

TUESDAY, Nov. 12, 2024 -- A cutting-edge genetic test can rapidly detect and identify almost any kind of disease-causing microorganism in the human body, whether it’s a virus, bacteria, fungus or parasite, researchers say. Doctors have been using the genetic test for more than a decade to identify pathogens in spinal fluid, after its development at the University of California-San Francisco. And now researchers have adapted the test to identify germs in respiratory fluid that can cause pneumonia, according to a new study published Nov. 12 in the journal Nature Medicine . The research team also has automated the test, which is called metagenomic next-generation sequencing or mNGS, the study says. The new respiratory version of the mNGS test requires just 30 minutes of hands-on time before robots and AI take over, and can return results in time to treat dangerous infections, researchers said. “Our goal was to have the entire process completed within 12 to 24 hours, giving a same-day or next-day result,” senior researcher Dr. Charles Chiu , a professor of laboratory medicine and infectious diseases at UCSF, said in a news release. The mNGS test takes a bare-knuckled approach to analysis. Rather than looking for single types of pathogen one by one, the test analyzes all RNA and DNA that are present in a sample, then separates human genetic material from those that originate in bacteria, viruses, fungi or parasites. “Our technology is deceptively simple,” Chiu said. “By replacing multiple tests with a single test, we can take the lengthy guesswork out of diagnosing and treating infections.” The mNGS test first made waves back in 2014 when doctors used it to save the life of then-15-year-old Joshua Osborn, who’d come down with debilitating headaches, fever, weight loss and fatigue. Osborn, who lived in Cottage Grove, Wisc., eventually fell into a coma with life-threatening encephalitis – and still no one could figure out what was making him sick. Medical tests and a brain biopsy brought back nothing. But once mNGS was employed, the test sussed out the cause within 48 hours. It wound up being Leptospira santarosai , a bacterial species native to Puerto Rico. As it turns out, Osborn and his family had visited a church camp there a year before his hospitalization. The remedy for the disease, that had plagued him for more than a year, wound up being old-fashioned penicillin. “I’m happy to be living,” Osborn said at the time. “By the percentages, the likelihood is pretty much that I wouldn’t be. I’m thankful.” Between 2016 and 2023, the UCSF team analyzed nearly 5,000 spinal fluid samples with the test, more than 14% of which turned out to have an infection. Overall, the test accurately identified the pathogen in spinal fluid 86% of the time, researchers say in their new paper. “Our mNGS test performs better than any other category of test for neurologic infections,” Chiu said, “The results support its use as a critical part of the diagnostic armamentarium for physicians who are working up patients with infectious diseases.” Based on these results, researchers have adapted the test to serve as a rapid-response system for respiratory diseases that could become the basis of the world’s next pandemic. The new report shows that the test can detect respiratory viruses like COVID, influenza and RSV in less than a day, even if there’s only small amounts of virus present in a sample. The test also should be able to detect strains expected to emerge in the future. Both the spinal fluid and respiratory droplet versions of the mNGS test have received breakthrough device designation from the U.S. Food and Drug Administration, placing them on a fast track for full approval. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

突破性疗法临床研究

2024-10-22

·PRNewswire

Two Scientists Win March of Dimes Basil O'Connor Grants to Advance Artificial Womb for Preterm Babies, Sickle Cell Screening for Newborns in Sub-Saharan Africa

ARLINGTON, Va., Oct. 22, 2024 /PRNewswire/ -- March of Dimes, the leading organization fighting for the health of all moms and babies, has awarded two physician-scientists the Basil O'Connor Starter Scholar Research Award, the organization's signature grants for up-and-coming scientists embarking on lifelong research paths. Continue Reading Dr. Emily Partridge, MD, PhD, MHS, a pediatric and fetal surgeon at The Children's Hospital of Philadelphia (CHOP) and an assistant professor of surgery at the University of Pennsylvania, and Dr. Hojun Li, MD, PhD, a pediatric hematologist and assistant professor of pediatrics at the University of California, San Diego, each received $150,000 grants. "Our Basil O'Connor awards have a rich history, with past winners going on to make truly outstanding achievements." Post this Dr. Partridge's work will build upon her existing research to advance the artificial womb, a fluid-filled sac modeled after the uterus made to improve developmental outcomes for extremely preterm babies, those babies born at or before 25 weeks of pregnancy. Her research focuses on adding liquid ventilation to the womb's breathing mechanism. This process uses a special chemical in the baby's lungs to aid breathing, prevent infections and strengthen the lungs in preparation for withdrawal from the artificial womb. Dr. Partridge anticipates that once the baby is out of the artificial womb, they will continue to use the liquid ventilation to further strengthen their lungs before placement on a regular ventilator in the neonatal intensive care unit. Dr. Li will use his grant to build upon the creation of a simple, portable, and effective test that will identify newborns with sickle cell anemia, a condition that impacts about 1 in 2,000 babies in the US and more acutely impacts people of African descent. Sickle cell disease causes mutant hemoglobin molecules to stretch out red blood cells, making them unable to fit through blood vessels and deliver oxygen, ultimately leading to infections, severe pain, stroke, and other life-threatening conditions. His test will focus on babies born in Sub-Saharan Africa, where 250,000 babies are born each year with the condition, with 95% of those dying in the first five years due to infection and other sickle-cell-related complications. The test developed by Dr. Li and then Massachusetts Institute of Technology master's student Amelia Seabold, now at University of Oxford in England, along with others, will use genome editing technology CRISPR to identify the mutated sickle cell gene within minutes from a single drop of blood. Dr. Li's goal is to see the test distributed to health workers in Sub-Saharan Africa who make home visits to postpartum moms. Babies diagnosed with the disease can be given penicillin, which promises to dramatically improve life expectancy and quality of life. "Our Basil O'Connor awards have a rich history, with past winners going on to make truly outstanding achievements in the field of maternal and infant health," said March of Dimes Chief Scientific Advisor Dr. Emre Seli. "Drs. Partridge and Li are two shining stars in our field, and we couldn't be prouder to support their work for preterm babies and those with sickle cell disease. Their vital research is poised not only to dramatically change outcomes for moms and babies globally, but to pave new scientific paths for the young physician-scientists who walk in their footsteps to reduce preventable maternal and infant mortality and morbidity." The Basil O'Connor awards, named for the first March of Dimes chairman and president, are part of March of Dimes' research strategy to address the multi-faceted nature of the maternal and infant health crisis with funding that supports discovery, translational and social science research, and data collection and analysis. Find more information about the Basil O'Connor Awards here. About March of Dimes March of Dimes leads the fight for the health of all moms and babies. We support research, education, and advocacy, and provide programs and services so that every family can have the best possible start. Since 1938, we've built a successful legacy to support every pregnant person and every family. Visit marchofdimes.org or nacersano.org for more information. Find us on Facebook and follow us with #marchofdimes and @marchofdimes. SOURCE March of Dimes Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-09-24

·PRNewswire

Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance (AMR)

First diagnostic company to pledge support towards collaborative efforts for real-world solutions to a global problem. SUNNYVALE, Calif., Sept. 24, 2024 /PRNewswire/ -- Cepheid announced today an important partnership with the Fleming Initiative, a global collaboration established by Imperial College Healthcare NHS Trust and Imperial College London to combat antimicrobial resistance. The Fleming Initiative and Cepheid will introduce the partnership at an event in New York aligned with the United Nations General Assembly High Level Meeting about AMR1. The Fleming Initiative brings together research scientists, policymakers, clinicians, behavioral experts, public and commercial partners to provide the networks, expertise and skills to provide equitable solutions to AMR at the global scale. "Almost everyone who has visited a healthcare provider for an undiagnosed infection has taken antibiotics as a preventative measure at one time in our lives. Too often, we are given broad spectrum antibiotics for viral infections or allergic reactions instead of as a treatment for a bacterial infection. That's how antimicrobial resistance develops," said Vitor Rocha, President of Cepheid. "Accurate diagnostics are at the frontline of the battle to eliminate preventative antibiotic use. Every one of us can help reduce unnecessary antibiotic use by requesting an accurate diagnostic test to identify the source of an infection before we begin a course of antibiotics." The Initiative will draw on diverse expertise and public involvement to tackle antimicrobial resistance from all angles. The partners will work together to catalyze worldwide action in the fight against AMR where poverty, climate change, and health inequality exacerbate the issues caused by drug-resistant infections. "At the Fleming Initiative we aim to unlock powerful new ideas to drive significant change in the fight against AMR. This requires collective innovation across industries, from practitioners to policy-makers and the public," said Professor the Lord Darzi of Denham, Executive Chair of the Fleming Initiative. "I am delighted to welcome Cepheid as our first diagnostics partner. Currently 20% of antibiotic prescriptions given in primary care lack an appropriate diagnosis. We have to do better. Cepheid's expertise will be essential to our efforts to ensure antibiotics work for generations to come." AMR is widely recognized by the World Health Organization as one of the top ten public health threats in the world. A study published this month in the Lancet2 found that resistance to antibiotics has led to over one million deaths each year since 1990. The study predicts increasing rates of drug-resistant infections will cause annual deaths to rise from 1.14 million in 2021 to 1.91 million in 2050 and forecasts that without further policy interventions, global deaths will reach 39 million between 2025 and 2050—the equivalent of three deaths per minute. Cepheid's significant pledge to the Fleming Initiative will be used for collaborative scientific and clinical research, with a focus on strengthening and expanding the use of in vitro diagnostics to support antimicrobial stewardship programs to enable responsible antibiotic use and control the rise of resistant infections. The collaboration will focus initially on the most critical areas of AMR: Encourage active screening for carbapenemase-producing Enterobacteriaceae (CPE) for earlier detection of critical infections and colonization Implementation of community-based acute respiratory infection (ARI) testing and care pathways to provide decentralized diagnostic and treatment pathways Accelerate a precision medicine approach for sepsis to identify and treat patients with a particular sepsis response state About Antimicrobial Resistance (AMR) AMR occurs when microbes including bacteria, viruses, fungi and parasites change over time and no longer respond to the drugs and treatments society relies on to kill them and prevent disease. If measures are not urgently implemented to combat AMR, the consequences will be far reaching. Uncomplicated infections and minor injuries could once again become life-threatening. AMR kills over one million people around the world each year3 and is a growing challenge in treating leading infectious disease killers such as tuberculosis, Escherichia coli (E. coli), and Methicillin-resistant Staphylococcus aureus (MRSA). It has been caused in part by the widespread misuse and overuse of antibiotics and other antimicrobial medicines, in humans and livestock, which has led to the global spread of drug-resistant microbes. To effectively tackle AMR, global awareness and behavior change is needed. About Cepheid Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid's broad test portfolio spans respiratory infections, blood virology, women's and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company's solutions deliver actionable results where they are needed most – from central laboratories and hospitals to near-patient settings. For more information, visit . Fleming Initiative The Fleming Initiative has a strong focus on diagnostics so that the right antimicrobial drugs are given to those who need them, as well as focusing on education and public engagement to support behavioural change to reduce drug-resistant infections. Launched through a partnership between Imperial College Healthcare NHS Trust and Imperial College London, the Fleming Centre will combine cutting edge research, public engagement, and work with policymakers to drive a global change. Earlier this year global biopharma company GSK became the first founding partner of the Initiative, with a pledge of £45m. The international work of the Initiative will be carried out by establishing a global network of centres in strategic locations around the world that will find, test, and scale solutions to AMR. Taking an enabling and scaling role, the first Fleming Centre will be based at St Mary's Hospital in London - at the site of the discovery of penicillin by Alexander Fleming in 1928 - and will form a key part of the Imperial's WestTech Corridor and Paddington Life Sciences. As Patron of the appeal to create the Fleming Initiative, His Royal Highness Prince William, the Prince of Wales, is supporting efforts over the next four years to develop this global HQ for the Fleming Initiative programmes. About Imperial College London Imperial College London is a global top ten university with a world-class reputation. Imperial's 22,000 students and 8,000 staff are working to solve the biggest challenges in science, medicine, engineering and business. Imperial ranks sixth in the 2024 QS World University Rankings and eighth in the 2024 Times Higher Education World University Rankings. The 2021 Research Excellence Framework (REF) found that it has a greater proportion of world-leading research than any other UK university. It also received a Gold Award in the 2023 Teaching Excellence Framework (TEF). Imperial was named University of the Year in the Daily Mail University Guide 2024, University of the Year for Graduate Employment in The Times and Sunday Times Good University Guide 2024, and awarded a Queen's Anniversary Prize for its COVID-19 response. For more information, visit . 1UN General Assembly High-Level Meeting on antimicrobial resistance 2024 2Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 (Accessed Sept. 2024) Naghavi, Mohsen et al. The Lancet, Volume 0, Issue 0 3World Health Organization: Antimicrobial resistance (Accessed Sept. 2024) For Cepheid Media Inquiries: Darwa Peterson [email protected] SOURCE Cepheid WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与苄星青霉素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02157	苄星青霉素	J01CE08	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
梅毒	日本	Pfizer Japan, Inc.	2021-09-27
感染	中国	苏州二叶制药有限公司	1982-01-01
细菌感染	美国	King Pharmaceuticals LLC	1952-06-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02611765 (CTgov)	临床4期	梅毒 \| 合并感染	64	Benzathine penicillin G intramuscular 7.2 million units (Enhanced Therapy)	遞壓艱鏇餘憲齋膚遞窪(壓餘醖簾夢獵糧簾觸遞) = 窪襯鹹繭壓襯鏇鏇憲顧餘繭鬱鬱齋遞齋淵顧鏇 (窪齋遞鑰夢鹽顧願廠製, 觸構繭衊築繭築構網鏇 ~ 積構簾鬱積構壓獵壓顧) 更多	-	2016-04-11
				Benzathine penicillin G intramuscular 2.4 million units (Standard Therapy)	遞壓艱鏇餘憲齋膚遞窪(壓餘醖簾夢獵糧簾觸遞) = 範夢願鑰觸艱襯範糧廠餘繭鬱鬱齋遞齋淵顧鏇 (窪齋遞鑰夢鹽顧願廠製, 選製艱簾簾築鏇襯選餘 ~ 鏇鬱齋鹹蓋範醖餘餘選) 更多
NCT01382004 (Pubmed \| Lancet)	临床3期	雅司病	255	Azithromycin	鬱壓鏇遞築醖觸壓醖鑰(遞選膚襯鹽遞獵餘糧艱) = 憲衊夢艱構壓壓壓鏇鑰構艱衊鬱網鑰積製壓壓 (構淵憲醖鑰衊遞網鏇膚 )	积极	2012-01-28
				Benzathine benzylpenicillin	鬱壓鏇遞築醖觸壓醖鑰(遞選膚襯鹽遞獵餘糧艱) = 襯衊鹹衊遞網憲構齋餘構艱衊鬱網鑰積製壓壓 (構淵憲醖鑰衊遞網鏇膚 )
NCT00031499 (Pubmed \| Am J Trop Med Hyg)	临床3期	梅毒	517	Azithromycin 2.0 g	(鬱餘膚憲獵憲積範夢夢) = Nonserious adverse events were more common among azithromycin recipients than they were among penicillin recipients (61.5% vs 46.3%), and such adverse events were accounted for, in large part, by self-limited gastrointestinal complaints. 積願齋積齋網淵齋壓醖 (範選願廠觸壓醖顧壓淵 )	积极	2010-06-01
				Benzathine penicillin G 2.4 million units